 - Arm I: Patients receive vaccine therapy comprising multi-epitope melanoma peptides MP, tetanus toxoid helper peptide TET, and sargramostim GM-CSF emulsified in Montanide ISA-51 transdermally TD on days 1, 8, and 15. Patients then receive the vaccine intradermally ID and subcutaneously SC on days 29, 50, 71, 92, 113, and 134. 